Ua ʻāpono ʻia nā papa Glecirasib Citrate no ka hoʻokuʻu ʻana i ka mākeke, e wehe ana i kahi mokuna hou ma ka mālama ʻana o KRASG12C-Mutated Advanced NSCLC

Ma ka lā 22 o Mei, 2025, ua hoʻolaha ʻo Allist Pharmaceuticals ua ʻae kūhelu ʻia kāna lāʻau lapaʻau hou ʻo Airuikai (Glecirasib Citrate Tablets), he mea hoʻopaʻa KRAS-G12C, no ka hoʻomaka ʻana i ka mākeke e ka National Medical Products Administration (NMPA). ʻAe ka ʻae ʻia iā Airuikai e hoʻohana ʻia no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi kanesa māmā non-small cell holomua (NSCLC) KRAS®®G12C i loaʻa mua ma ka liʻiliʻi hoʻokahi laina o ka lāʻau lapaʻau systemic. Hōʻailona kēia i kahi lāʻau lapaʻau kanesa māmā hou i ʻae ʻia no Allist Pharmaceuticals, e hāʻawi ana i kahi koho lapaʻau hou no nā poʻe maʻi me ka maʻi kanesa māmā non-small cell KRASG12C i hoʻololi ʻia (NSCLC) a kōkua i ka hoʻoponopono hou ʻana i ke ʻano lapaʻau no kēia ʻano maʻi kanesa paʻakikī e mālama.

Hoʻokumu ʻia ka ʻāpono ʻana ma nā hopena mai kahi noiʻi lima hoʻokahi o ka Phase II e loiloi ana i ka palekana, ka hoʻomanawanui, a me ka pono o ka monotherapy Glecirasib i nā poʻe maʻi me ka maʻi ʻaʻai māmā liʻiliʻi ʻole e hūnā ana i nā mutations KRASG12C i hāʻule ʻole a i ʻole i hoʻomanawanui ʻole i nā lāʻau lapaʻau maʻamau.

Ua hōʻike nā hopena he pono a hoʻomanawanui maikaʻi ʻo Goleresai. Ma ka lā 28 o Kepakemapa, 2024, ua hoʻokomo ʻia he 119 mau maʻi NSCLC i ka loiloi. ʻO ka helu pane i hōʻoia ʻia (cORR), e like me ka loiloi ʻana a ke Kōmike Loiloi Kūʻokoʻa (IRC), he 49.6% (40.2%-59.0%), me ka helu kaohi maʻi (DCR) o 86.3% (78.7%-92.0%). ʻO ka lōʻihi waena o ka pane (DOR) he 14.5 mau mahina (9.6 mau mahina a hiki ʻole ke kuhi ʻia), ʻo ka awelika o ke ola ʻole o ka holomua (PFS) he 8.2 mau mahina (5.2–11.1), a ʻo ka awelika o ke ola holoʻokoʻa (OS) he 17.5 mau mahina (13.6 mau mahina a hiki ʻole ke kuhi ʻia).

I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.

Helu Kelepona：4008803716

Email：myimmnet@163.com